PT - JOURNAL ARTICLE AU - Fujisawa, Ryosuke AU - Iwaya, Takeshi AU - Endo, Fumitaka AU - Idogawa, Masashi AU - Sasaki, Noriyuki AU - Hiraki, Hayato AU - Tange, Shoichiro AU - Hirano, Tomomi AU - Koizumi, Yuka AU - Abe, Masakazu AU - Takahashi, Tomoko AU - Yaegashi, Mizunori AU - Akiyama, Yuji AU - Masuda, Mari AU - Sasaki, Akira AU - Takahashi, Fumiaki AU - Sasaki, Yasushi AU - Tokino, Takashi AU - Nishizuka, Satoshi S. TI - Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer AID - 10.1101/2021.02.25.21251979 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.25.21251979 4099 - http://medrxiv.org/content/early/2021/03/05/2021.02.25.21251979.short 4100 - http://medrxiv.org/content/early/2021/03/05/2021.02.25.21251979.full AB - Purpose We investigated whether early circulating tumor DNA (ctDNA) changes, measured using digital PCR (dPCR), can predict later chemotherapy responses in esophageal squamous cell cancer (ESCC).Design We compared the dynamics of ctDNA and tumor volumes during chemotherapy in 42 ESCC. The accuracy of predictions of later chemotherapy responses were evaluated by the ratio of the variant allele frequency (VAF) of ctDNA (post-/pre-ctDNA) and the total tumor volume (post-/pre-volume) before and after an initial chemotherapy cycle using a receiver-operating characteristic curve analysis. Total positive and negative objective responses (ORs) were defined as either >50% or ≤50% reductions, respectively, in the total tumor volume at the end of first-line chemotherapy.Results Mutation screening of 43 tumors from 42 patients revealed 96 mutations. The pretreatment dPCR-ctDNA data were informative in 38 patients, using 70 selected mutations (1–3 per patient). The areas under the curve (AUCs) for the post-/pre-volume and post-/pre-ctDNA levels used in predicting the total OR were 0.85 and 0.88, respectively. The optimal cutoff value of post-/pre-ctDNA was 0.13. In 90% (18/20) of patients with a post-/pre-volume ≥50%, the total OR could be predicted by the post-/pre-ctDNA with high accuracy; the AUC by post-/pre-ctDNA was higher than that by post-/pre-volume (0.85 vs 0.76, respectively). Patients with low post-/pre-ctDNA (n = 18) had a significantly better overall survival rate than those with high post-/pre-ctDNA (n = 20; P = 0.03).Conclusions Early ctDNA changes after an initial cycle of chemotherapy predict later responses to treatment with high accuracy in ESCC patients.Competing Interest StatementDr. Iwaya received grant/research support from Nippon Kayaku, Chugai Pharmaceutical, and Daiichi Sankyo. Dr. Nishizuka received grant/research support form Array Jet, Taiho Pharmaceuticals, Boehringer-Ingelheim, Chugai Pharmaceutical, and Geninus. Dr. Nishizuka is an advisor/board member of CLEA Japan. Drs. Iwaya and Nishizuka hold a patent that might benefit from this publication (JP6544783). Dr. Akira Sasaki grant/research support from Takeda Pharmaceutical, Taiho Pharmaceutical, Otsuka Pharmaceutical, and Teijin Pharma.Clinical TrialUMIN000038724Funding StatementThis work was supported by Keiryokai Collaborative Research Grant [#131, #136] and a Grant-in-Aid for Scientific Research KAKENHI [JP16H01578, JP16K19951, JP16K19952, JP16H06279, JP17K10605, 19K09224, and 20K09064].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of Iwate Medical University (IRB# HGH27-16 and HG2020-021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data were deposited in the DNA Data Bank Japan (Accession number JGAS00000000219).